Glucagon-like peptide-1 - A new hormone and a new drug;Glukagonlignende peptide-1 - Et nyt hormon og et nyt loegemiddel

Ugeskrift for Laeger

Volumn 160, Issue 16, 1998, Pages 2371-2377

  Holst, Jens Juul ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; NEW DRUG; GLUCAGON RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; DRUG MECHANISM; GENE MUTATION; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; INSULIN RELEASE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; ANIMAL; ARTICLE; CHEMISTRY; DRUG EFFECT; GENETICS; PHYSIOLOGY;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCAGON; HUMANS; MICE; RECEPTORS, GLUCAGON;

EID: 0032513397     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Holst JJ. Extrapancreatic glucagons. Digestion 1978; 17: 168-90.
2. Holst JJ. Evidence that glicentin contains the entire glucagon sequence. Biochem J 1980; 187: 337-43.
3. Holst JJ. Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. Biochem J 1982; 207: 381-8.
4. Thim L, Moody AJ. The primary structure of glicentin (proglucagon). Regul Pept 1981; 2: 139-51.
5. Moody AJ, Hoist JJ, Thim L, Jensen SL Relationship of glicentin to proglucagon and glucagon in the porcine pancreas. Nature 1981; 289: 514-6.
6. Holst JJ. Gut glucagon, enteroglucagon, gut GLI, glicentin - current status. Gastroenterology 1983, 84: 1602-13.
7. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature 1983; 304: 368-71.
8. Holst JJ, Orskov AC, Schwarte TW, Nielsen OV. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 1987; 211: 169-74.
9. Ørskov C, Bersani M, Johnsen AH, Højrup P, Holst JJ. Complete sequences of glucagon-like peptide-1 (GLP-1) from human and pig small intestine. J Biol Chem 1989; 264: 12826-9.
10. Ørskov C, Holst JJ, Knuhtsen S, Baldissera FGA, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2. predicted products of the glucagon gene, are secreted separately from the pig small intestine, but not pancreas Endocrinology 1986; 119: 1467-75.
11. Holst JJ, Bersani M, Johnsen AH, Kofod H, Hartmann B, Ørskov C. Proglucagon processing in porcine and human pancreas. J Biol Chem 1994; 269: 18827-33.
12. Holst JJ, Orskov C, Schwartz TW, Buhl T, Baldissera FGA. Proglucagon 78-107, a potent insulinotropic hormone from lower small intestine. Diabetologia 1986; 29: 549A
13. Ørskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 (proglucagon 78-107 amide) on endocrine secretion from pig pancreas, antrum and stomach Endocrinology 1988; 123: 2009-13.
14. Hvidberg A, Nielsen MT, Hilsted J, Ørskov C, Holst JJ. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism 1994; 43: 104-8.
15. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of GLP-I (7-36amide) but not of synthetic human GIP in patients with type 2-diabetes mellitus. J Clin Invest 1993; 36: 741-4.
16. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycemia by exogenous GLP-1 (7-36amide) in type 2-diabetic patients. Diabetologia 1993; 36: 741-4.
17. Holst JJ. Enteroglucagon. Ann Rev Physiol 1997, 59: 257-72.
18. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 72-107amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-73.
19. Wettergren A, Petersen H, Ørskov C, Christiansen J, Sheikh SP, Holst JJ. Glucagon-like peptide-1 (GLP-1) 7-36amide and peptide YY from the L-cell in the ileal mucosa are potent inhibitors of vagally induced gastric acid in man. Scand J Gastroenterol 1994, 29: 501-5.
20. Thorens B, Porret A, Buhler L, Deng S-H, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin 4 is an agonist and exendin 9-39 an antagonist of the receptor. Diabetes 1993; 42: 1678-82.
21. Kolligs F, Fehmann HC, Goke R, Göke B. Reduction of the incretin effect in rats by the glucagon-like peptide-1 receptor antagonist exendin (9-39)amide. Diabetes 1995; 44: 16-9.
22. Scrocchi LA, Brown TJ, MacLusky N, Brubaker PL, Auerbach AB, Joyner Al et al Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nature Med 1996; 2: 1254-8.
23. Holz GG, Kühltreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose competent by the insulinotropic hormone glucagon-like peptide-1 (7-37). Nature 1993, 361: 362-5.
24. Toft-Nielsen M, Madsbad S, Holst JJ. The effect of GLP-1 on glucose elimination. Diabetes 1996; 45: 552-6.
25. Ørskov L, Holst JJ, Ørskov C, Møller N, Alberti KGMM, Schmitz O. GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 1995; 39: 1227-32.
26. Wettergren A, Wøjdemann M, Meisner S, Stadil F, Holst JJ. The inhibitory effect of glucagon-like peptide-1 7-36amide on gastric acid secretion in man depends on an intact vagal innervation. Gut 1997; 40: 597-601.
27. Ørskov C, Poulsen SS, Møller M, Holst JJ. GLP-1 receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide-1. Diabetes 1996; 45: 832-5.
28. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Schmiegel WH. Inhibition of gastric emptying by physiological and pharmacological doses of exogenous glucagon-like peptide 1 (GLP-1) outweighs insulinotropic effects in healthy normoglycemic volunteers. Am J Physiol (i trykken).
29. Larsen PJ, Tang-Christensen M, Holst JJ, Ørskov C. Distribution of glucagon-like peptide-1 (GLP-1) and other preproglucagon derived peptides in the rat hypothalamus and brain stem. Neuroscience 1997; 77. 257-70.
30. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Mccran K et al. A role for glucagon-like peptide-1 in the regulation of feeding. Nature 1996; 379: 69-72
31. Creutzfeldt W, Kleine N, Willms B, Ørskov C, Holst JJ, Nauck MA Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide-1 (7-36amide) in type I diabetic patients. Diabetes Care 1996; 19: 580-6.
32. Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses and insulin secretion after a liquid test meal: effects of glucagon-like peptide-1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327-32.
33. Larsen J, Jallad N, Damsbo P. One-week continuous infusion of GLP-1(7-37) improves glycemic control in NIDDM. Diabetes 1996; 45. (suppl 2): 233A.
34. Ritzel R, Ørskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 (7-36 amide) after subcutaneous injection in healthy volunteers. Dose-response relationships. Diabetologia 1995; 38: 720-5.
35. Deacon CF, Johnsen AH, Holst JJ Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminaily truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80. 952-7.
36. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B. Holst JJ. Both subcutaneous and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-31.
37. Ørskov C, Andreasen J, Holst JJ. Proglucagon products in plasma of uraemic patients and normals in the fasting state. J Clin Endocrinol Metab 1992; 74. 379-84.
38. Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with type 2-diabetes. Diabetologia 1996; 39 1546-53.
39. Qualmann C, Nauck MA, Holst JJ, Ørskov C, Creulzfeldt W. Glucagon-like peptide-1 (GLP-1) [7-36amide] secretion in response to luminal sucrose from, the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995; 30: 892-6.
40. Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ahren B. Potentially therapeutic levels of glucagon-like peptide-1 achieved in humans by a buccal tablet. Diabetes Care 1996; 19: 843-8.